GSA Capital Partners LLP Sells 3,015 Shares of OmniAb, Inc. (NASDAQ:OABI)

GSA Capital Partners LLP lowered its position in shares of OmniAb, Inc. (NASDAQ:OABI) by 3.2% in the third quarter, HoldingsChannel reports. The fund owned 91,437 shares of the company’s stock after selling 3,015 shares during the period. GSA Capital Partners LLP’s holdings in OmniAb were worth $387,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Janus Henderson Group PLC increased its position in shares of OmniAb by 1.0% during the 1st quarter. Janus Henderson Group PLC now owns 7,859,438 shares of the company’s stock worth $42,598,000 after purchasing an additional 81,541 shares during the last quarter. Vanguard Group Inc. increased its holdings in OmniAb by 1.1% during the first quarter. Vanguard Group Inc. now owns 5,713,539 shares of the company’s stock worth $30,967,000 after buying an additional 62,131 shares during the last quarter. Dimensional Fund Advisors LP raised its position in OmniAb by 6.9% during the second quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock worth $11,296,000 after acquiring an additional 194,835 shares in the last quarter. Rice Hall James & Associates LLC lifted its stake in OmniAb by 6.4% in the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after acquiring an additional 163,038 shares during the last quarter. Finally, Woodstock Corp grew its position in shares of OmniAb by 5.6% in the 3rd quarter. Woodstock Corp now owns 792,853 shares of the company’s stock valued at $3,354,000 after acquiring an additional 42,310 shares during the period. 72.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Benchmark reiterated a “buy” rating and issued a $8.00 target price on shares of OmniAb in a research note on Thursday, November 14th. Royal Bank of Canada restated an “outperform” rating and set a $7.00 target price on shares of OmniAb in a research note on Friday, August 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Stock Down 1.3 %

NASDAQ OABI opened at $3.85 on Friday. The company has a market cap of $454.92 million, a price-to-earnings ratio of -6.21 and a beta of -0.12. The business has a 50 day moving average price of $4.15 and a 200-day moving average price of $4.25. OmniAb, Inc. has a 52 week low of $3.56 and a 52 week high of $6.72.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.